GLP-1 Market
LLY $1354.00 ▼ -0.8% NVO $40.31 ▲ +0.0% PFE $29.39 ▼ -1.6% VKTX $26.84 ▲ +4.1% KLRA $12.97 ▲ +6.6% GPCR $20.35 ▲ +6.7% RHHBY $59.37 ▼ -0.1%
Market data delayed up to 20 min · Source: Twelve Data

Empowering you to have better conversations with your doctor.

Subscribe
About this data Sourced primarily from ClinicalTrials.gov — a listing isn't proof of safety or FDA approval.

Pipeline and clinical trial information here comes primarily from ClinicalTrials.gov. A listing on ClinicalTrials.gov means a study has been registered — not that a treatment is proven safe, effective, or FDA-approved. Investigational treatments may never be approved. Who can join a trial is decided only by that trial's own study team.

Not yet reported

Adenuric

Company
University Hospital, Rouen
Mechanism
Mechanism not yet reported
Route
Route not yet reported
Recruiting trials
None currently listed

Efficacy results: Not yet reported

No recruiting studies currently listed

See all studies for this drug

Data source: ClinicalTrials.gov · trial data as of Nov 7, 2026

Trial details
  • Completed NCT NCT01724528

    Febuxostat for Tumor Lysis Syndrome Prevention in Hematologic Malignancies

    Not yet reported Menarini Group 346 participants Est. completion 2013-10
    Other conditions: Tumor Lysis Syndrome
    View official trial listing →
  • Completed NCT NCT01736514

    A Study to Evaluate Safety and Efficacy of Oral Febuxostat in Patients With Gout

    Not yet reported Astellas Pharma Taiwan, Inc. 109 participants Est. completion 2012-02 4 sites
    Other conditions: Gout
    View official trial listing →
  • Completed NCT NCT02338323

    Compare the Renal Protective Effects of Febuxostat and Benzbromarone

    Not yet reported Shanghai 10th People's Hospital 160 participants Est. completion 2018-12 1 site
    Chronic kidney disease Other conditions: Hyperuricemia, Abnormal Renal Function
    View official trial listing →
  • Completed NCT NCT02500641

    Intensive Urate Lowering Therapy of Febuxostat Compared to Allopurinol on Cardiovascular Risk in Patients With Gout

    Not yet reported Menarini International Operations Luxembourg SA 196 participants Est. completion 2017-05-10 26 sites
    Other conditions: Gout
    View official trial listing →
  • Status unknown NCT NCT02944214

    Compare the Renal Protective Effects of Febuxostat and Benzbromarone in CKD Chinese Patients

    Not yet reported Shanghai 10th People's Hospital 800 participants Est. completion 2019-12 1 site
    Chronic kidney disease Other conditions: Hyperuricemia, Abnormal Renal Function
    View official trial listing →
  • Completed NCT NCT03395977

    Uric Acid Effects on Endothelium and Oxydative Stress

    Not yet reported Erasme University Hospital 53 participants Est. completion 2020-02-27 1 site
    Other conditions: Oxidative Stress, Endothelial Function, Cardiovascular System, Hypertension
    View official trial listing →
  • Terminated NCT NCT03605212

    Febuxostat for Tumor Lysis Syndrome Prevention in Hematological Malignancies of Paediatric Patients and Adults

    Not yet reported, Not yet reported Menarini Group 30 participants Est. completion 2018-07-25 17 sites Stand-alone
    Other conditions: Tumor Lysis Syndrome
    View official trial listing →
  • Completed NCT NCT03918551

    Bioequivalence Study of Two Formulations of Febuxostat 120 mg Film-coated Tablets in Healthy Adult Volunteers After a Single Oral Dose Administration Under Fasting Conditions

    Not yet reported Pharmtechnology LLC 50 participants Est. completion 2019-06-06 1 site
    Other conditions: Bioequivalence
    View official trial listing →
  • Completed NCT NCT04155918

    Phase 2a Study of AR882 Alone and in Combination With Febuxostat or Allopurinol in Gout Patients

    Not yet reported Arthrosi Therapeutics 30 participants Est. completion 2020-09-03 1 site
    Other conditions: Gout Patients
    View official trial listing →
  • Status unknown NCT NCT04352153

    Role of Uralyt-U in Patients With Hyperuricemia

    Not yet reported Ai Peng 102 participants Est. completion 2020-10-31 1 site
    Other conditions: Uric Acid Stones, Hyperuricemia
    View official trial listing →
  • Completed NCT NCT05109936

    Immediate Prescription of a Hypouricemic Treatment, Febuxostat, Compared to Its Delayed Administration

    Not yet reported University Hospital, Rouen 9 participants Est. completion 2026-08-10 6 sites Stand-alone
    Other conditions: Gout
    View official trial listing →
Efficacy history

Not yet reported.

Safety

Not yet reported.

Sources
Related On The Pen coverage

No related coverage yet.

This drug may be investigational and not yet approved for any use. Whether someone can join a clinical trial is determined only by that trial's own study team — On The Pen does not determine eligibility. Information here can change; always confirm current details on the official ClinicalTrials.gov listing or with the sponsor.